tbuckley/cabot-search huggingface dataset:
Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives
Authors: Hanyu Ni, Elizabeth Jordan, Daniel D. Kinnamon, Jinwen Cao, Garrie J. Haas, Mark Hofmeyer, Evan Kransdorf, Gregory A. Ewald, Alanna A. Morris, Anjali Owens, Brian Lowes, Douglas Stoller, W.H. Wilson Tang, Sonia Garg, Barry H. Trachtenberg, Palak Shah, Salpy V. Pamboukian, Nancy K. Sweitzer, Matthew T. Wheeler, Jane E. Wilcox, Stuart Katz, Stephen Pan, Javier Jimenez, Daniel P. Fishbein, Frank Smart, Jessica Wang, Stephen S. Gottlieb, Daniel P. Judge, Charles K. Moore, Gordon S. Huggins, Ray E. Hershberger
Journal: Journal of the American College of Cardiology (2023)
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership
Authors: Jasmijn Z Jagt, Patrick F van Rheenen, Sophia M A Thoma, Jonathan Gower, Pamela B Reimering-Hartgerink, Heidi J H L van der Wielen, Esther J van Steenbergen, Anne-Marije Goutbeek, Elisabeth M van Dijk-Lokkart, Stijn Vlietstra, Dana Reinders, Yanniek den Otter, Isabella Schoonderwoert, Bas Schoonderwoert, Hannie Schoonderwoert, Germa van der Weide, Simone van Harten, Kees Mouthaan, Marc A Benninga, Nanne K H de Boer, Daniëlle van der Horst, Menne Scherpenzeel, Tim G J de Meij
Journal: The Lancet. Gastroenterology & hepatology (2023)
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
Authors: Marco Guazzi, Marco Vicenzi, Ross Arena, Maurizio D. Guazzi
Journal: Circulation (2011)

Background— The prevalence of heart failure with preserved ejection fraction is increasing. The prognosis worsens with pulmonary hypertension and right ventricular (RV) failure development. We targeted pulmonary hypertension and RV burden with the phosphodiesterase-5 inhibitor sildenafil. Methods and Results— Forty-four patients with heart failure with preserved ejection fraction (heart failure signs and symptoms, diastolic dysfunction, ejection fraction ≥50%, and pulmonary artery systolic pressure &gt;40 mm Hg) were randomly assigned to placebo or sildenafil (50 mg thrice per day). At 6 months, there was no improvement with placebo, but sildenafil mediated significant improvements in mean pulmonary artery pressure (−42.0±13.0%) and RV function, as suggested by leftward shift of the RV Frank-Starling relationship, increased tricuspid annular systolic excursion (+69.0±19.0%) and ejection rate (+17.0±8.3%), and reduced right atrial pressure (−54.0±7.2%). These effects may have resulted from changes within the lung (reduced lung water content and improved alveolar-capillary gas conductance, +15.8±4.5%), the pulmonary vasculature (arteriolar resistance, −71.0±8.2%), and left-sided cardiac function (wedge pulmonary pressure, −15.7±3.1%; cardiac index, +6.0±0.9%; deceleration time, −13.0±1.9%; isovolumic relaxation time, −14.0±1.7%; septal mitral annulus velocity, −76.4±9.2%). Results were similar at 12 months. Conclusions— The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage). These results enhance our understanding of heart failure with preserved ejection fraction and offer new directions for therapy. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01156636.
Manipulating the Dynamic Adaptivity of a Fluid Interface to Maintain the Multipotency of Mesenchymal Stromal Cells
Authors: Wenyan Lyu, Wei Hu, Jiaming Shi, Jieman Chen, Jingwen Song, Qindan Zhang, Xuefeng Yuan, Dairui Li, Jun Nakanishi, Xiaofang Jia
Journal: Advanced Healthcare Materials (2023)

The native extracellular matrix is highly dynamic with continuous mutual feedback between cells being responsible for many important cell function regulators. However, establishing bidirectional interaction between complex adaptive microenvironments and cells remains elusive. Herein an adaptive biomaterial based on lysozyme monolayers self-assembled at a perfluorocarbon FC40-water interface is reported. The dynamic adaptivity of interfacially assembled protein nanosheets is modulated independently of bulk mechanical properties by covalent crosslinking. This provides a scenario to establish bidirectional interactions of cells with liquid interfaces of varying dynamic adaptivity. This is found that growth and multipotency of human mesenchymal stromal cells (hMSCs) are enhanced at the highly adaptive fluid interface. The multipotency retention of hMSCs is mediated by low cell contractility and metabolomic activity involving the continuous mutual feedback between the cells and materials. Consequently, an understanding of the cells' response to dynamic adaptivity has substantial implications for regenerative medicine and tissue engineering.
Melanoma cells in optical super-high magnification dermoscopy
Authors: Joanna Pogorzelska-Dyrbuś, Jacek C Szepietowski
Journal: British Journal of Dermatology (2023)

Journal Article Corrected proof Melanoma cells in optical super-high magnification dermoscopy Get access Joanna Pogorzelska-Dyrbuś, Joanna Pogorzelska-Dyrbuś ‘Estevita’ Specialist Medical Practice, Tychy, Poland Search for other works by this author on: Oxford Academic Google Scholar Jacek C Szepietowski Jacek C Szepietowski Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland Correspondence: Jacek C. Szepietowski. Email: jacek.szepietowski@umw.edu.pl https://orcid.org/0000-0003-0766-6342 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad168, https://doi.org/10.1093/bjd/ljad168 Published: 22 May 2023 Article history Received: 17 January 2023 Revision received: 25 April 2023 Accepted: 17 May 2023 Published: 22 May 2023 Corrected and typeset: 23 June 2023
Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction
Authors: Maria Vistnes, Pugazendhi Murugan Erusappan, Athiramol Sasi, Einar Sjaastad Nordén, Kaja Knudsen Bergo, Andreas Romaine, Ida Gjervold Lunde, Lili Zhang, Maria Belland Olsen, Jonas Øgaard, Cathrine Rein Carlson, Christian Hjorth Wang, Jon Riise, Christen Peder Dahl, Arnt Eltvedt Fiane, Ida Marie Hauge-Iversen, Emil Espe, Arne Olav Melleby, Theis Tønnessen, Jan Magnus Aronsen, Ivar Sjaastad, Geir Christensen
Journal: Cardiovascular Research (2023)

Heart failure is a condition with high mortality rates, and there is a lack of therapies that directly target maladaptive changes in the extracellular matrix (ECM), such as fibrosis. We investigated whether the ECM enzyme known as A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) 4 might serve as a therapeutic target in treatment of heart failure and cardiac fibrosis.The effects of pharmacological ADAMTS4 inhibition on cardiac function and fibrosis were examined in rats exposed to cardiac pressure overload. Disease mechanisms affected by the treatment were identified based on changes in the myocardial transcriptome. Following aortic banding, rats receiving an ADAMTS inhibitor, with high inhibitory capacity for ADAMTS4, showed substantially better cardiac function than vehicle-treated rats, including ∼30% reduction in E/e' and left atrial diameter, indicating an improvement in diastolic function. ADAMTS inhibition also resulted in a marked reduction in myocardial collagen content and a down-regulation of transforming growth factor (TGF)-β target genes. The mechanism for the beneficial effects of ADAMTS inhibition was further studied in cultured human cardiac fibroblasts producing mature ECM. ADAMTS4 caused a 50% increase in the TGF-β levels in the medium. Simultaneously, ADAMTS4 elicited a not previously known cleavage of TGF-β-binding proteins, i.e. latent-binding protein of TGF-β and extra domain A-fibronectin. These effects were abolished by the ADAMTS inhibitor. In failing human hearts, we observed a marked increase in ADAMTS4 expression and cleavage activity.Inhibition of ADAMTS4 improves cardiac function and reduces collagen accumulation in rats with cardiac pressure overload, possibly through a not previously known cleavage of molecules that control TGF-β availability. Targeting ADAMTS4 may serve as a novel strategy in heart failure treatment, in particular, in heart failure with fibrosis and diastolic dysfunction.
Determinants of ventricular arrhythmias in sickle cell anemia: toward better prevention of sudden cardiac death
Authors: Thomas d’Humières, Joseph Saba, Laurent Savale, Marie Dupuy, Laurent Boyer, Henri Guillet, Lara Alassaad, Gonzalo de Luna, Sihem Iles, Anne L. Pham Hung d'Alexandry d'Orengiani, Yosr Zaouali, Nouhaila Boukour, Yanis Pelinski, Laurent Messonier, Etienne Audureau, Haytham Derbel, Anoosha Habibi, Nicolas Lellouche, Geneviève Derumeaux, Pablo Bartolucci
Journal: Blood (2023)
Temporal Trends in the Use of Computed Tomographic Pulmonary Angiography for Suspected Pulmonary Embolism in the Emergency Department
Authors: Melanie Roussel, Ben Bloom, Mehdi Taalba, Christophe Choquet, Delphine Douillet, Florent Fémy, Alexis Marouk, Judith Gorlicki, Camille Gerlier, Richard Macrez, Emilien Arnaud, Rudy Bompard, Emmanuel Montassier, Olivier Hugli, Charlotte Czopik, Xavier Eyer, Axel Benhamed, Olivier Peyrony, Tahar Chouihed, Andrea Penaloza, Alessio Marra, Said Laribi, Paul-Georges Reuter, Wilhelm Behringer, Marion Douplat, Jeremy Guenezan, Nicolas Javaud, Olivier Lucidarme, Marine Cachanado, Ainhoa Aparicio-Monforte, Yonathan Freund, Mouna Berroukeche, Anthony Chauvin, Anne-Charlotte Dekeister, Mostafa El Hajjam, Sami Ellouze, Olivier Ganansia, Julien Grosjean, Quentin Le Bastard, Thomas Moumneh, Milan Najdawi, Laurent Pereira, Isabelle Piazza, Sarah Ponticello, Jason Pott, Clément Ricordeau, Julie Robert, Pascal Rousset, Imogen Skene, Clara Vignau, Youri Yordanov
Journal: Annals of Internal Medicine (2023)

Background: Recently, validated clinical decision rules have been developed that avoid unnecessary use of computed tomographic pulmonary angiography (CTPA) in patients with suspected pulmonary embolism (PE) in the emergency department (ED). Objective: To measure any resulting change in CTPA use for suspected PE. Design: Retrospective analysis. Setting: 26 European EDs in 6 countries. Patients: Patients with CTPA performed for suspected PE in the ED during the first 7 days of each odd month between January 2015 and December 2019. Measurements: The primary end points were the CTPAs done for suspected PE in the ED and the number of PEs diagnosed in the ED each year adjusted to an annual census of 100 000 ED visits. Temporal trends were estimated using generalized linear mixed regression models. Results: 8970 CTPAs were included (median age, 63 years; 56% female). Statistically significant temporal trends for more frequent use of CTPA (836 per 100 000 ED visits in 2015 vs. 1112 in 2019; P < 0.001), more diagnosed PEs (138 per 100 000 in 2015 vs. 164 in 2019; P = 0.028), a higher proportion of low-risk PEs (annual percent change [APC], 13.8% [95% CI, 2.6% to 30.1%]) with more ambulatory management (APC, 19.3% [CI, 4.1% to 45.1%]), and a lower proportion of intensive care unit admissions (APC, −8.9% [CI, −17.1% to −0.3%]) were observed. Limitation: Data were limited to 7 days every 2 months. Conclusion: Despite the recent validation of clinical decision rules to limit the use of CTPA, an increase in the CTPA rate along with more diagnosed PEs and especially low-risk PEs were instead observed. Primary Funding Source: None specific for this study.
Subepicardial Cardiomyopathy: A Disease Underlying J-Wave Syndromes and Idiopathic Ventricular Fibrillation
Authors: Chris Miles, Bastiaan J. Boukens, Chiara Scrocco, Arthur A.M. Wilde, Koonlawee Nademanee, Michel Haissaguerre, Ruben Coronel, Elijah R. Behr
Journal: Circulation (2023)

Brugada syndrome (BrS), early repolarization syndrome (ERS), and idiopathic ventricular fibrillation (iVF) have long been considered primary electrical disorders associated with malignant ventricular arrhythmia and sudden cardiac death. However, recent studies have revealed the presence of subtle microstructural abnormalities of the extracellular matrix in some cases of BrS, ERS, and iVF, particularly within right ventricular subepicardial myocardium. Substrate-based ablation within this region has been shown to ameliorate the electrocardiographic phenotype and to reduce arrhythmia frequency in BrS. Patients with ERS and iVF may also exhibit low-voltage and fractionated electrograms in the ventricular subepicardial myocardium, which can be treated with ablation. A significant proportion of patients with BrS and ERS, as well as some iVF survivors, harbor pathogenic variants in the voltage-gated sodium channel gene,
Telomeres Fuse During Cardiomyocyte Maturation
Authors: Esther Aix, Alex Gallinat, Carla Yago-Díez, Javier Lucas, Manuel José Gómez, Alberto Benguría, Patricia Freitag, Elizabeth Cortez-Toledo, Laura Fernández de Manuel, Lucía García-Cuasimodo, Héctor Sánchez-Iranzo, María C. Montoya, Ana Dopazo, Fátima Sánchez-Cabo, Nadia Mercader, Javier E. López, Bernd K. Fleischmann, Michael Hesse, Ignacio Flores
Journal: Circulation (2023)
Palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML
Authors: Xuejing Shao, Aixiao Xu, Wenxin Du, Tong Xu, Yunpeng Huang, Zhimei Xia, Wei Wang, Minyi Cai, Xingya Zhang, Jianhua Zhang, Ji Cao, Xiaojun Xu, Bo Yang, Qiaojun He, Meidan Ying
Journal: Blood (2023)
Accumulation of Chronic Disease Among Survivors of Childhood Cancer Predicts Early Mortality
Authors: Adam J. Esbenshade, Lu Lu, Debra L. Friedman, Kevin C. Oeffinger, Gregory T. Armstrong, Kevin R. Krull, Joseph P. Neglia, Wendy M. Leisenring, Rebecca Howell, Robyn Partin, Amy Sketch, Leslie L. Robison, Kirsten K. Ness
Journal: Journal of Clinical Oncology (2023)

Cancer survivors develop cancer and treatment-related morbidities at younger than normal ages and are at risk for early mortality, suggestive of an aging phenotype. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) is specifically designed to describe the accumulation of comorbidities over time with estimates of severity such as total score (TS) which is a sum of possible conditions weighted by severity. These severity scores can then be used to predict future mortality.
Silent cerebral infarction during immune TTP remission - prevalence, predictors, and impact on cognition
Authors: Shruti Chaturvedi, Jia Yu, Jenna Brown, Aria Wei, Sruthi Selvakumar, Gloria F Gerber, Alison R. Moliterno, Michael B. Streiff, Peggy Kraus, Claire Maylor Logue, Jennifer C Yui, Rakhi P. Naik, Hira Latif, Sophie Lanzkron, Evan M. Braunstein, Robert A. Brodsky, Rebecca F. Gottesman, Doris D Lin
Journal: Blood (2023)
Population-Wide Screening for Chronic Kidney Disease
Authors: Marika M. Cusick, Rebecca L. Tisdale, Glenn M. Chertow, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
Journal: Annals of Internal Medicine (2023)

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have the potential to alter the natural history of chronic kidney disease (CKD), and they should be included in cost-effectiveness analyses of screening for CKD. Objective: To determine the cost-effectiveness of adding population-wide screening for CKD. Design: Markov cohort model. Data Sources: NHANES (National Health and Nutrition Examination Survey), U.S. Centers for Medicare & Medicaid Services data, cohort studies, and randomized clinical trials, including the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial. Target Population: Adults. Time Horizon: Lifetime. Perspective: Health care sector. Intervention: Screening for albuminuria with and without adding SGLT2 inhibitors to the current standard of care for CKD. Outcome Measures: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), all discounted at 3% annually. Results of Base-Case Analysis: One-time CKD screening at age 55 years had an ICER of $86 300 per QALY gained by increasing costs from $249 800 to $259 000 and increasing QALYs from 12.61 to 12.72; this was accompanied by a decrease in the incidence of kidney failure requiring dialysis or kidney transplant of 0.29 percentage points and an increase in life expectancy from 17.29 to 17.45 years. Other options were also cost-effective. During ages 35 to 75 years, screening once prevented dialysis or transplant in 398 000 people and screening every 10 years until age 75 years cost less than $100 000 per QALY gained. Results of Sensitivity Analysis: When SGLT2 inhibitors were 30% less effective, screening every 10 years during ages 35 to 75 years cost between $145 400 and $182 600 per QALY gained, and price reductions would be required for screening to be cost-effective. Limitation: The efficacy of SGLT2 inhibitors was derived from a single randomized controlled trial. Conclusion: Screening adults for albuminuria to identify CKD could be cost-effective in the United States. Primary Funding Source: Agency for Healthcare Research and Quality, Veterans Affairs Office of Academic Affiliations, and National Institute of Diabetes and Digestive and Kidney Diseases.
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation
Authors: Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson L. Dickson, Katherine T. Murray
Journal: Annals of Internal Medicine (2023)

Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding. For patients receiving apixaban or rivaroxaban, to compare risk for bleeding-related hospitalizations during treatment with amiodarone versus flecainide or sotalol, antiarrhythmic drugs that do not inhibit these anticoagulants' elimination. Retrospective cohort study. U.S. Medicare beneficiaries aged 65 years or older. Patients with atrial fibrillation began anticoagulant use between 1 January 2012 and 30 November 2018 and subsequently initiated treatment with study antiarrhythmic drugs. Time to event for bleeding-related hospitalizations (primary outcome) and ischemic stroke, systemic embolism, and death with or without recent (past 30 days) evidence of bleeding (secondary outcomes), adjusted with propensity score overlap weighting. There were 91 590 patients (mean age, 76.3 years; 52.5% female) initiating use of study anticoagulants and antiarrhythmic drugs, 54 977 with amiodarone and 36 613 with flecainide or sotalol. Risk for bleeding-related hospitalizations increased with amiodarone use (rate difference [RD], 17.5 events [95% CI, 12.0 to 23.0 events] per 1000 person-years; hazard ratio [HR], 1.44 [CI, 1.27 to 1.63]). Incidence of ischemic stroke or systemic embolism did not increase (RD, -2.1 events [CI, -4.7 to 0.4 events] per 1000 person-years; HR, 0.80 [CI, 0.62 to 1.03]). The risk for death with recent evidence of bleeding (RD, 9.1 events [CI, 5.8 to 12.3 events] per 1000 person-years; HR, 1.66 [CI, 1.35 to 2.03]) was greater than that for other deaths (RD, 5.6 events [CI, 0.5 to 10.6 events] per 1000 person-years; HR, 1.15 [CI, 1.00 to 1.31]) (HR comparison: P = 0.003). The increased incidence of bleeding-related hospitalizations for rivaroxaban (RD, 28.0 events [CI, 18.4 to 37.6 events] per 1000 person-years) was greater than that for apixaban (RD, 9.1 events [CI, 2.8 to 15.3 events] per 1000 person-years) (P = 0.001). Possible residual confounding. In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol. National Heart, Lung, and Blood Institute.
The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21
Authors: Qingsong Gao, Sarra L. Ryan, Ilaria Iacobucci, Pankaj S. Ghate, Ruth E. Cranston, Claire Schwab, Abdelrahman H. Elsayed, Lei Shi, Stanley Pounds, Shaohua Lei, Pradyuamna Baviskar, Deqing Pei, Cheng Cheng, Matthew Bashton, Paul Sinclair, David R. Bentley, Mark T. Ross, Zoya Kingsbury, Terena James, Kathryn G. Roberts, Meenakshi Devidas, Yiping Fan, Wenan Chen, Ti-Cheng Chang, Gang Wu, Andrew Carroll, Nyla Heerema, Virginia Valentine, Marcus Valentine, Wenjian Yang, Jun J. Yang, Anthony V. Moorman, Christine J. Harrison, Charles G. Mullighan
Journal: Blood (2023)
Annals Graphic Medicine - Why Bedside Rounds Need Bedside Language
Authors: Rebekah L. Gardner, Vinald W. Francis, Daniel Baxter, Kate Cahill
Journal: Annals of Internal Medicine (2023)

Web Exclusives23 May 2023Annals Graphic Medicine - Why Bedside Rounds Need Bedside LanguageFREERebekah L. Gardner, MD, Vinald W. Francis, BFA, and Daniel Baxter, BFA, and Kate Cahill, MDRebekah L. Gardner, MDAlpert Medical School of Brown University, Providence, Rhode Island (R.L.G., K.C., V.W.F.)Search for more papers by this author, Vinald W. Francis, BFAAlpert Medical School of Brown University, Providence, Rhode Island (R.L.G., K.C., V.W.F.)Search for more papers by this author, and Daniel Baxter, BFAGlenshaw, Pennsylvania (D.B.)Search for more papers by this author, and Kate Cahill, MDAlpert Medical School of Brown University, Providence, Rhode Island (R.L.G., K.C., V.W.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G22-0044 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Author, Article, and Disclosure InformationAuthors: Rebekah L. Gardner, MD; Vinald W. Francis, BFA; Daniel Baxter, BFA; Kate Cahill, MDAffiliations: Alpert Medical School of Brown University, Providence, Rhode Island (R.L.G., K.C., V.W.F.)Glenshaw, Pennsylvania (D.B.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G22-0044.Author/Illustrator Information: Rebekah L. Gardner, MD, is an academic general internal medicine physician and graphic medicine enthusiast (e-mail, rebekah_gardner@brown.edu). Vinald W. Francis, BFA, is a medical illustrator and visual design specialist (e-mail, vinald_francis@brown.edu). Daniel Baxter, BFA, is an artist and musician (e-mail, danielabaxter@mac.com). Kate Cahill, MD, is a general internal medicine physician and clinician–educator (e-mail, kate_cahill@brown.edu).This article was published at Annals.org on 23 May 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics June 2023Volume 176, Issue 6 ePublished: 23 May 2023 Issue Published: June 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Appraising the causal role of smoking in idiopathic pulmonary fibrosis: a Mendelian randomization study
Authors: Jiahao Zhu, Dan Zhou, Min Yu, Yingjun Li
Journal: Thorax (2023)

Smoking has been considered a risk factor for idiopathic pulmonary fibrosis (IPF) in observational studies. To assess whether smoking plays a causal role in IPF, we performed a Mendelian randomization study using genetic association data of 10 382 cases with IPF and 968 080 controls. We found that genetic predisposition to smoking initiation (based on 378 variants) and lifetime smoking (based on 126 variants) were associated with a higher risk of IPF. Our study suggests a potential causal effect of smoking on increasing IPF risk from a genetic perspective.